

Shareholders increase their involvement in the development of Mabion Company received a loan from a shareholder for the repayment of credit in Santander bank

On 15th July 2020, Mabion S.A. concluded a loan agreement in the amount of PLN 15 million with the company Glatton Sp. z o.o. controlled by Maciej Wieczorek, - an affiliated entity and a shareholder holding directly and indirectly a total of 11.85% of Mabion shares. The loan is intended to fully refinance the credit granted to Mabion in 2018 by Santander Bank Polska S.A., from which so far Mabion has used only PLN 15 million. The loan repayment date to the shareholder was set at 31 December 2020, with the possibility of extending this date.

- Granting a borrowing to repay a loan from Santander Bank, I hereby confirm my long-term commitment to Mabion's development. The borrowing repayment deadline is set for the end of this year, but if necessary, the deadline can be extended - says **Dr. Maciej Wieczorek, Deputy Chairman of the Supervisory Board of Mabion S.A.**

- The loan to repay the credit granted to us by one of our major shareholders is a major support for us in the process of building external financing to bring our flagship project - the MabionCD20 drug to registration and to the commercial stage. This is also an important signal that our founding shareholders are ready to increase their involvement in the development of Mabion in the long term. At the same time, I would like to emphasize that the obtained loan is additional financing, which is not part of the capital injection declared in March by the company's main shareholders with an amount not lower than PLN 15 million in 2020 - says **Grzegorz Grabowicz, Member of the Management Board and CFO at Mabion S.A.**

According to the agreement, the interest rate on the loan was agreed on market terms as a variable interest rate based on WIBOR 3M plus margin. The loan is secured by (among others) a mortgage on real estate located in Konstantynów Łódzki up to PLN 45 million.

About the Company:

Mabion is the first Polish biotechnology company whose primary objective is to develop, manufacture and market biosimilar drugs for several regulated markets.

The Company's lead project is MabionCD20. The Company is pursuing registration under the centralized procedure for all European markets in a partnership with Mylan - one of the largest pharmaceutical companies in the world. Another medium-term goal of the Company is to introduce MabionCD20 to the American market. In addition, the Company pursues MabionMS (MabionCD20 for the treatment of multiple sclerosis) and MabionEGFR.

Since 2013, Mabion has been listed on the WSE's main market. The company is included in the mWIG40 index.

Find more information at: www.mabion.eu.



Media contact:

Michał Wierzchowski

cc group

phone: +48 531 613 067

e-mail: michal.wierzchowski@ccgroup.pl